Sacral Erector Spinae Plane Block, Pilonidal Sinus
Conditions
Brief summary
This study aims to evaluate the efficacy of ultrasound-guided Sacral Erector Spinae Plane (ESP) block for postoperative analgesia management in patients undergoing pilonidal sinus surgery under general anesthesia
Detailed description
Severe pain after pilonidal sinus surgery is a significant problem that reduces patient comfort. In this randomized, prospective study, patients will be divided into two groups (Sacral ESPB group and control group) using a computer randomization method before the surgery. In the Sacral ESPB group, the block will be performed under ultrasound guidance using a 20 ml local anesthetic volume immediately after the surgical procedure and before extubation. The study will compare postoperative rescue analgesic requirement, opioid consumption, pain scores (NRS), and the incidence of side effects and complications
Interventions
PROCEDURESacral Erector Spinae Plane Block
Immediately after the surgical procedure and before extubation, ultrasound-guided (Vivid Q) Sacral ESPB will be applied to the patient in the prone position using a total volume of 20 ml.
No block will be applied to this group. Both groups will receive intravenous 400 mg ibuprofen and 100 mg tramadol 20 minutes before the end of the surgery, and routine 1000 mg paracetamol every 8 hours postoperatively
Sponsors
Medipol University
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Outcomes Assessor)
Masking description
Single Blind (Outcomes Assessor). Postoperative patient evaluation will be performed by another anesthesiologist who was not involved in the procedure.
Eligibility
Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No
Inclusion criteria
* Patients scheduled for elective pilonidal sinus surgery. * ASA physical status I and II
Exclusion criteria
* Allergy or sensitivity to local anesthetics or opioid drugs. * Infection at the block site. * Alcohol or drug addiction. * Use of anticoagulant agents. * Patient refusal.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Total postoperative rescue analgesic (opioid) consumption. | At 24 hours postoperatively (Cumulative total over the 24-hour period) | Total amount of intravenous tramadol administered as a rescue analgesic will be recorded |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Postoperative pain scores evaluated by the Numeric Rating Scale (NRS) | At 1, 3, 6, 12, 18, and 24 hours postoperatively. | Pain scores will be evaluated at rest and during movement using a 0-10 NRS (0= no pain, 10= most severe pain). |
| Incidence of opioid-related side effects and block-related complications. | During the 24-hour postoperative period. | Occurrence of side effects such as nausea, vomiting, itching, allergic reactions, and complications like hematoma will be recorded. |
Countries
Turkey (Türkiye)
Outcome results
None listed